Plantation, FL. – October 7, 2013 – Neurotrope, Inc. (formerly BlueFlash Communications, Inc.) (OTCQB:NTRP), a Nevada corporation (the “Company”), announced today that it has formally hired Robert Weinstein to be its Executive Vice President and Chief Financial Officer. Mr. Weinstein had been the acting Chief Financial Officer, as a consultant, since May 2013 and was instrumental in executing the Company’s private financings and reverse merger, which both closed in August 2013.

Prior to joining Neurotrope, Mr. Weinstein was a financial and accounting consultant to several healthcare companies in the pharmaceutical, medical device and biotechnology industries. Prior to his consulting roles, Mr. Weinstein was the Chief Financial Officer of three publicly traded companies, consistently increasing shareholder value through an active role in investor relations while partnering with senior management to provide strategic guidance and leading all Securities and Exchange Commission filing compliance. Prior to his senior officer and consulting positions, Mr. Weinstein was a founding partner in a highly successful healthcare-oriented private equity fund and an investment banker focused on micro-cap company financings and mergers & acquisitions.

He is a certified public accountant and earned his Masters of Business Administration at The University of Chicago Graduate School of Business.

About Neurotrope

Neurotrope was formed in October 2012 to develop and market two product platforms, including a non-invasive diagnostic test for Alzheimer’s Disease and a drug candidate called bryostatin for the treatment of Alzheimer’s Disease, both of which are in the clinical testing stage. Neurotrope was formed for the primary purpose of commercializing certain technologies that were initially developed by Blanchette Rockefeller Neurosciences Institute (“BRNI”) and its affiliates, for therapeutic or diagnostic applications for Alzheimer’s Disease or other cognitive dysfunctions. These technologies have been under development since 1999 and have been financed through significant funding from a variety of non-investor sources. The Company expects that its first product, the diagnostic test for Alzheimer’s Disease, will finish the testing phase of its development in 2015, whereupon the Company will evaluate the feasibility of its commercialization. In addition to bryostatin and the diagnostic test for Alzheimer’s Disease, the Company intends to pursue development of two other technology platforms developed by and licensed from BRNI: the first, a platform for transporting drugs into the brain through the “blood-brain-barrier,” and the second, a group of drugs for enhancing cognition, mood and alertness for neuropsychiatric conditions.

Please visit www.neurotropebioscience.com for further information.

Forward-Looking Statements

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Forward-looking statements may include, without limitation, statements regarding (i) the plans and objectives of management for future operations, including plans or objectives relating to the development of commercially viable pharmaceuticals, (ii) a projection of income (including income/loss), earnings (including earnings/loss) per share, capital expenditures, dividends, capital structure or other financial items, (iii) the Company’s future financial performance and (iv) the assumptions underlying or relating to any statement described in points (i), (ii) or (iii) above. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be realized because they are based upon the Company’s current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to a number of risks and uncertainties and other influences, many of which the Company has no control over. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, the Company’s inability to obtain adequate financing, the significant length of time associated with drug development and related insufficient cash flows and resulting illiquidity, the Company’s inability to expand the Company’s business, significant government regulation of pharmaceuticals and the healthcare industry, lack of product diversification, volatility in the price of the Company’s raw materials, existing or increased competition, results of arbitration and litigation, stock volatility and illiquidity, and the Company’s failure to implement the Company’s business plans or strategies. These and other factors are identified and described in more detail in the Company’s filings with the SEC, including, the Company’s current reports on Form 8-K. The Company does not undertake to update these forward-looking statements.

For additional information, please contact:

Investor Relations:
Investor Awareness, Inc.
Tony Schor, 847-945-2222 ext. 221
tony@investorawareness.com
www.InvestorAwareness.com

The Company:
Robert Weinstein
Chief Financial Officer
(914) 295-2765
rweinstein@neurotropebioscience.com
www.neurotropebioscience.com